CJC-1295 and Ipamorelin: GHRH-Axis Research at a Glance

Few research blends are as iconic in the growth-hormone-axis literature as CJC-1295 with Ipamorelin. Together they engage two distinct signaling routes that converge on pulsatile GH release — a pairing that lets researchers separate GHRH-driven and ghrelin-driven contributions to the same endpoint.

CJC-1295: a GHRH analog

CJC-1295 is a synthetic 30-amino-acid GHRH analog. The unmodified (no-DAC) form has a shorter half-life, generating discrete GH pulses similar in shape to endogenous secretion — useful when researchers want temporally resolved data rather than continuously elevated GH/IGF-1.

Ipamorelin: a selective ghrelin-receptor agonist

Ipamorelin is a pentapeptide that selectively activates the GHS-R1a (ghrelin) receptor. Crucially, in published studies it shows minimal effects on ACTH, cortisol, or prolactin — making it the cleanest available probe for isolating GHS-R1a signaling without confounding HPA-axis activation.

Why the pairing

GHRH and ghrelin pathways act synergistically at the somatotroph. Combining the two in research protocols typically produces larger and more reproducible GH pulses than either alone, while preserving the selective signaling profile of each component. This makes the pair valuable for dose-response characterization and downstream IGF-1 kinetics work.

Storage

Lyophilized blends should be stored at -20°C. Once reconstituted, refrigerated vials are typically usable for ~21 days. Document reconstitution date on each vial to maintain protocol integrity.

Sold for laboratory research only. Not for human consumption.